-
Key Brands
-
Statistics
-
Revenue
-
Contribution
-
Market data
| Durateston | Lipitor | Lyrica | Meticorten | Ovestin | Perfalgan |
|---|---|---|---|---|---|
| Testosterone replacement therapy | Anti-epileptic drugs | Corticosteroid | Statin lipid modifying agent | Estrogen hormone replacement | Injectable analgesic |
10
Products
Launched
Launched
(2024: 66)
0
Product
Recalls
Recalls
(2024: 1)
0
%
Average Staff
Turnover
Turnover
(2024: 29%)
0
Work-related
Fatalities
Fatalities
(2024: Nil)
100
Sales
Representatives
Representatives
(2024: 303)
610
Permanent
Employees
Employees
June 2025
600
Permanent
Employees
Employees
(June 2024)
5
Products
Launched
Launched
(2022: 20)
Product
Recalls
Recalls
(2022: 1)
5
%
Average Staff
Turnover
Turnover
(2022: 22)
Work-related
Facilities
Facilities
(2022: Nil)
135
Sales
Representatives
Representatives
(2022: 235)
250
Permanent
Employees
Employees
(June 2022: 714)
| Revenue | 2025 R'million |
2024 (CER) R'million |
Change % |
|---|---|---|---|
| Commercial Pharmaceuticals | 6 826 | 5 855 | 17 |
| Prescription | 3 320 | 2 483 | 34 |
| Injectables | 2 177 | 2 091 | 4 |
| Over the counter | 1 329 | 1 281 | 4 |
| Manufacturing | |||
| Finished dose form | 17 | 33 | (48) |
| Total | 6 843 | 5 888 | 16 |
Note: Commercial Pharmaceuticals' revenue is by customer geography and Manufacturing revenue is by place of manufacture.
CER: Constant Exchange Rate
CER: Constant Exchange Rate
Contribution to Group revenue (%)
2025
Rest of Group
84
Americas
16
Revenue by segment (%)
2025
Prescription
49
Injectables
32
Over the counter
19
- Latin America is expected to grow at a compound annual growth rate of 7,8% between 2025 and 2029*.
- The Viatris portfolio, acquired on 1 November 2023, has demonstrated a successful transition following the acquisition, supported by sustained half-on-half growth. This portfolio revenue has increased by 34,0% since July 2023.
Source: IQVIA Institute, March 2025.
